Home Meetings Online CME/CE Clinical Resources Amazing Charts
Skip Navigation Links.
Activity Information
Activity
Finish

Online CME Activity

The Lung in COPD: What’s Left


NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.

Title:
The Lung in COPD: What’s Left
Release Date:
07/06/2010
Expiration Date:
07/06/2011
Topics:
COPD
Primary Audience:
Primary Care
Activity Format:
Expert Perspective
Credits:
0.50 AMA PRA Category 1 Credits™

 
Overall Satisfaction Rating:
Full Star Full Star Full Star Full Star Empty Star 77%

CME Information

Learning Objectives:

Utilize lung function testing to direct pharmacologic and adjunctive treatment approaches in moderate to severe COPD

Faculty:

Written By: R. Stokes Peebles, Jr., MD, FAAAAI, (Read Bio) , Associate Professor of Medicine, Vanderbilt University, Nashville, TN

Edited By: Carolyn Skowronski, PharmD, pmiCME

Financial Disclosures:

Dr Peebles serves on the advisory board for Merck.

Ms Skowronski discloses that she holds stock in Merck.

Nizar N. Jarjour, MD, Educational Content Reviewer, discloses that he has consulting relationships with Asthmatx and Genentech-Novartis, and research funding from GlaxoSmithKline, Merck & Co., and MedImmune.

Steven Folstein, Director of Education, American Academy of Allergy, Asthma and Immunology, has no financial relationships to disclose.

pmiCME along with the American Academy of Allergy, Asthma & Immunology (AAAAI) are part of the ACES (Asthma and COPD Education Solutions) Consortium. This national CME initiative is a coordinated effort to improve the standards of care for patients with non-contagious chronic respiratory conditions. Funding for this initiative is obtained from multiple sources including commercial support. Receipt of these funds is project based and acknowledged by the partner organizations that are responsible for those identified projects.

pmiCME and AAAAI receive funding from GlaxoSmithKline in support of this educational activity, which is part of the ACES Consortium initiative.

Commercial Support:

pmiCME and AAAAI, through the University of North Texas Health Science Center at Fort Worth, received funding from GlaxoSmithKline in support of this educational activity, which is part of the ACES Consortium initiative.

Education Partner:

American Academy of Allergy, Asthma & Immunology

Accreditation and Credit Designation:

This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with pmiCME's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of pmiCME.

Credits Type Accreditation Statement Designation Statement
0.50 AMA PRA Category 1 Credits™ pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. pmiCME designates this educational activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Instructions for Obtaining Credit:

Complete this activity. Answer the questions in the attached posttest and evaluation. Click on "claim credit" and follow the instructions to print out the credit certificate.